Amy Replogle

Amy Replogle is a seasoned professional with extensive experience in scientific strategy and clinical operations, currently serving as the Director of Scientific Strategy for Rx-to-OTC Switch at Bayer since October 2014. In this role, Amy leads the global evidence and access strategy for Rx-to-OTC innovation, emphasizing the integration of regulatory science, medical evidence, consumer insights, and advocacy to enhance patient self-care access. Key achievements include being recognized as a Science Fellow for pioneering strategies that have set new industry standards. Prior to Bayer, Amy held various positions at Merck from April 1999 to October 2002, advancing from project management to leadership roles in clinical research and evidence strategy related to Rx-to-OTC and lifecycle innovation. Amy holds a Bachelor of Science from Indiana University of Pennsylvania, a Master of Science from the University of Pennsylvania, and is pursuing a Doctor of Philosophy in Public Health and Epidemiology at Walden University.